EP4444361A4 - IN VIVO ADMINISTRATION TO IMMUNE CELLS - Google Patents

IN VIVO ADMINISTRATION TO IMMUNE CELLS

Info

Publication number
EP4444361A4
EP4444361A4 EP22905102.4A EP22905102A EP4444361A4 EP 4444361 A4 EP4444361 A4 EP 4444361A4 EP 22905102 A EP22905102 A EP 22905102A EP 4444361 A4 EP4444361 A4 EP 4444361A4
Authority
EP
European Patent Office
Prior art keywords
immune cells
vivo administration
vivo
administration
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22905102.4A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4444361A2 (en
Inventor
Michael Klichinsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carisma Therapeutics Inc
Original Assignee
Carisma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carisma Therapeutics Inc filed Critical Carisma Therapeutics Inc
Publication of EP4444361A2 publication Critical patent/EP4444361A2/en
Publication of EP4444361A4 publication Critical patent/EP4444361A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/39—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by a specific adjuvant, e.g. cytokines or CpG
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP22905102.4A 2021-12-09 2022-12-08 IN VIVO ADMINISTRATION TO IMMUNE CELLS Pending EP4444361A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163287725P 2021-12-09 2021-12-09
PCT/US2022/052207 WO2023107593A2 (en) 2021-12-09 2022-12-08 In vivo delivery to immune cells

Publications (2)

Publication Number Publication Date
EP4444361A2 EP4444361A2 (en) 2024-10-16
EP4444361A4 true EP4444361A4 (en) 2025-12-10

Family

ID=86731192

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22905102.4A Pending EP4444361A4 (en) 2021-12-09 2022-12-08 IN VIVO ADMINISTRATION TO IMMUNE CELLS

Country Status (4)

Country Link
EP (1) EP4444361A4 (https=)
JP (1) JP2024546641A (https=)
AU (1) AU2022407035A1 (https=)
WO (1) WO2023107593A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL313473A (en) 2021-12-15 2024-08-01 Interius Biotherapeutics Inc Pseudotyped viral particles, compositions comprising the same, and uses thereof
KR20250057777A (ko) 2022-07-25 2025-04-29 인테리우스 바이오테라퓨틱스, 인코포레이티드 돌연변이된 폴리펩티드, 이를 포함하는 조성물, 및 그 용도(mutated polypeptides, compositions comprising the same, and uses thereof)
CN117343908B (zh) * 2023-12-05 2024-02-09 南京大学 一种通过真菌精准激活的car-t细胞、制备方法、应用及药物组合物
WO2025235801A1 (en) 2024-05-08 2025-11-13 City Of Hope Antibodies targeted to osteopontin and uses thereof for reducing resistance of solid tumors immune cell therapy
CN120695211A (zh) * 2025-06-25 2025-09-26 广东医科大学附属医院 mRNA组合物及其在制备肝纤维化治疗药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170296676A1 (en) * 2016-04-14 2017-10-19 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
WO2020194306A1 (en) * 2019-03-26 2020-10-01 Gavish-Galilee Bio Applications Ltd. Genetically reprogrammed tregs expressing cars

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311901B2 (en) * 2003-10-10 2007-12-25 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
EP3561053A1 (en) * 2018-04-26 2019-10-30 Baylor College of Medicine Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy
IL295810B2 (en) * 2020-03-11 2026-01-01 Univ Pennsylvania Methods and compositions for gene delivery using a modified viral particle
JP7851254B2 (ja) * 2020-03-20 2026-04-24 オルナ セラピューティクス インコーポレイテッド 環状ｒｎａ組成物及び方法
CA3187138A1 (en) * 2020-06-26 2021-12-30 Carisma Therapeutics Inc. Mrna transfection of immune cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170296676A1 (en) * 2016-04-14 2017-10-19 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
WO2020194306A1 (en) * 2019-03-26 2020-10-01 Gavish-Galilee Bio Applications Ltd. Genetically reprogrammed tregs expressing cars

Also Published As

Publication number Publication date
EP4444361A2 (en) 2024-10-16
JP2024546641A (ja) 2024-12-26
AU2022407035A1 (en) 2024-05-23
WO2023107593A3 (en) 2023-07-27
WO2023107593A2 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
EP4444361A4 (en) IN VIVO ADMINISTRATION TO IMMUNE CELLS
FR26C1011I1 (fr) Composés thérapeutiquement actifs et leurs méthodes d'utilisation
IL286897A (en) Providing medical devices with sensing functionality
IL284924A (en) Local, concomitant administration of tolerogenic synthetic nanocarriers to reduce type i and type iv hypersensitivity
CL2018000457A1 (es) Anticuerpos anti-mesotelina completamente humanos y células con efecto inmune dirigido a la mesotelina
CY1120646T1 (el) Προγονικα κυτταρα μεσοδερμικης προελευσης
EP3362123A4 (en) MEDICAL LUER CONNECTION
EA201790109A1 (ru) Толерогенные синтетические наноносители, уменьшающие иммунный ответ на терапевтические белки
EP2970897A4 (en) IN VITRO PREPARATION OF PRECURSOR CELLS FOR MEDIUM GANGLIONIC EMINENCE
EP2560624A4 (en) THERAPEUTIC FORMULATION FOR REDUCED MEDICAMENT SIDE EFFECTS
EP3075218A4 (en) INTEGRATION OF A MICRO-INVERTER IN A PHOTOVOLTAIC MODULE
EP2970880A4 (en) MULTIFUNCTIONAL UNLIMITED TOOTHMARK STEM CELLS AND THERAPEUTIC APPLICATIONS
EA201692254A1 (ru) Иммуномодулирующие прогениторные (имп) клетки
IL243627A0 (en) High potency pancreatin pharmaceutical compositions
EA201591567A1 (ru) Новые производные пиридина
HUE053760T2 (hu) SUV39h1-deficiens immunsejtek
EP4167937A4 (en) PROBIOTIC SKIN FORMULATIONS
IL304559A (en) Self-polarizing immune cells
EP3549590A4 (en) CELL PREPARATION
EP3344760A4 (en) GENERALLY MANUFACTURED DRUG-RESISTANT T CELLS AND METHOD OF USE THEREOF
EP3926042A4 (en) ADJUVANTS TO PROMOTE THE EXPANSION OF IMMUNE CELLS IN VIVO
PL3511015T3 (pl) Genetycznie stabilna żywa atenuowana szczepionka przeciw syncytialnemu wirusowi oddechowemu i jej wytwarzanie
DK3307239T3 (da) Formuleringer til indgivelse af RSV- og norovirusantigener i tyndtarmen
EP4021465A4 (en) MANIPULATED IMMUNE CELLS
PL3880802T3 (pl) Udoskonalony sposób wytwarzania komórek T

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240709

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20251110

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 48/00 20060101AFI20251104BHEP

Ipc: A61K 35/17 20150101ALI20251104BHEP

Ipc: C12N 5/10 20060101ALI20251104BHEP

Ipc: C12N 15/85 20060101ALI20251104BHEP

Ipc: A61K 38/17 20060101ALI20251104BHEP

Ipc: C12N 5/0786 20100101ALI20251104BHEP

Ipc: A61K 40/17 20250101ALI20251104BHEP

Ipc: A61K 40/19 20250101ALI20251104BHEP

Ipc: A61K 40/31 20250101ALI20251104BHEP

Ipc: A61K 40/35 20250101ALI20251104BHEP

Ipc: C07K 14/54 20060101ALI20251104BHEP

Ipc: C07K 14/565 20060101ALI20251104BHEP

Ipc: C07K 14/715 20060101ALI20251104BHEP